The cell and gene therapy company Elicera Therapeutics has made important progress in two priority areas this year. This concerns investments in business development of the iTANK platform technology and obtaining conditional approval for the start of a phase I/IIa study with the CAR T-cell candidate ELC-301. This means that Elicera is now entering an exciting phase in an area where several significant transactions have been made recently.
Read the article at biostock.se:
https://www.biostock.se/en/2023/05/well-financed-elicera-prepared-for-clinic-and-business-development (https://www.biostock.se/en/2023/05/well-financed-elicera-prepared-for-clinic-and-business-development)
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/